Scilex Holding (SCLX) Change in Accured Expenses (2021 - 2026)
Scilex Holding (SCLX) posted quarterly Change in Accured Expenses of -$7.8 million for Q1 2026, down 1028.06% year-over-year from $841000.0 in Q1 2025, and down 2563.82% on a QoQ basis from -$293000.0 in Q4 2025.
Scilex Holding (SCLX) Change in Accured Expenses (2021 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Change in Accured Expenses for 6 consecutive years, with -$7.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 1028.06% year-over-year to -$7.8 million; the TTM figure through Mar 2026 stood at $6.0 million (up 170.51% YoY), while the FY2025 annual figure was $14.6 million, up 278.78% from the prior year.
- Change in Accured Expenses came in at -$7.8 million for Q1 2026 at Scilex Holding, down from -$293000.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $14.3 million in Q3 2025, with the low at -$10.6 million in Q4 2024.
- Average Change in Accured Expenses over 5 years is $32176.5, with a median of -$126000.0 recorded in 2022.
- Across the five-year window, Change in Accured Expenses plunged 19597.95% in 2022 and soared 29625.0% in 2023, its largest moves.
- Year by year, Change in Accured Expenses stood at $981000.0 in 2022, then tumbled by 427.73% to -$3.2 million in 2023, then tumbled by 230.64% to -$10.6 million in 2024, then surged by 97.24% to -$293000.0 in 2025, then sank by 2563.82% to -$7.8 million in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered -$7.8 million, -$293000.0, and $14.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | -629.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -1.59 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | -75.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | -702.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | -7.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.81 Mn |
| Mar 31, 2026 | -7.81 Mn |
| Dec 31, 2025 | -293,000.00 |
| Dec 31, 2025 | -293,000.00 |
| Sep 30, 2025 | 14.30 Mn |
| Sep 30, 2025 | 14.30 Mn |
| Jun 30, 2025 | -242,000.00 |
| Jun 30, 2025 | -242,000.00 |
| Mar 31, 2025 | 841,000.00 |
| Mar 31, 2025 | 841,000.00 |
| Dec 31, 2024 | -10.63 Mn |
| Dec 31, 2024 | -10.63 Mn |
| Sep 30, 2024 | 1.99 Mn |
| Sep 30, 2024 | 1.99 Mn |
| Jun 30, 2024 | -650,000.00 |
| Jun 30, 2024 | -650,000.00 |
| Mar 31, 2024 | 1.12 Mn |
| Mar 31, 2024 | 1.12 Mn |
| Dec 31, 2023 | -3.22 Mn |
| Dec 31, 2023 | -3.22 Mn |